Non-linear Elimination Processes of Theophylline
Overview
Authors
Affiliations
After intravenous and oral administration of theophylline to four healthy subjects, the plasma concentration-time curve of theophylline could be described by linear pharmacokinetics, although total clearance in all subjects decreased when the dose was increased; the doses were theophylline 193.2 mg and 386.4 mg i.v. and 161 mg and 322 mg p.o. Total clearance was 65.5 +/- 11.3 ml/min. Renal clearance changed from 15.2 +/- 9.5 ml/min in the first two hours after administration to 4.9 +/- 5.5 ml/min between 16 and 24 h (p less than 0.001). 1,3-dimethyluric acid (DMU), the major metabolite of theophylline, was determined in urine and in plasma. The renal clearance of DMU was constant at 496.7 +/- 180 ml/min. There was some evidence that at high plasma concentrations of theophylline the formation of DMU might be a zero-order process. The renal excretion rate of 1-methyluric acid (1-MU) paralleled that of DMU, which is in accordance with the assumption that DMU is demethylated to 1-MU. 3-methylxanthine (3-MX) was excreted in urine at a constant rate over 10 h, the rate being equivalent to the dose, which is contrary to the assumption of Michaelis-Menten-kinetics. 3-methyluric acid was found to be a minor metabolite of theophylline and 1-methylxanthine (1-MX) could not be detected. The cumulative amounts excreted in urine, expressed as a percentage of the dose and corrected for molecular weight, were theophylline 16.6 +/- 6.5%, DMU 44.3 +/- 7.0%, 1-MU 24.3 +/- 4.8%, 3-MX 12.9 +/- 3.4% and 3-MU 2.2 +/- 1.8%.
Liu L, Pan X, Liu H, Liu X, Yang H, Xie L Acta Pharmacol Sin. 2011; 32(10):1285-93.
PMID: 21892200 PMC: 4010077. DOI: 10.1038/aps.2011.78.
Dadashzadeh S, Tajerzaden H Eur J Drug Metab Pharmacokinet. 2001; 26(1-2):77-83.
PMID: 11554438 DOI: 10.1007/BF03190380.
KUH H, Shim C Arch Pharm Res. 1994; 17(2):124-30.
PMID: 10319144 DOI: 10.1007/BF02974236.
Niki Y, Itokawa K, Okazaki O Antimicrob Agents Chemother. 1998; 42(7):1751-5.
PMID: 9661016 PMC: 105678. DOI: 10.1128/AAC.42.7.1751.
Sato J, Nakata H, OWADA E, Kikuta T, Umetsu M, Ito K Eur J Clin Pharmacol. 1993; 44(3):295-8.
PMID: 8491248 DOI: 10.1007/BF00271376.